Report cover image

Myelodysplastic Syndrome: Competitive Landscape

Publisher GlobalData
Published Feb 28, 2025
Length 84 Pages
SKU # GBDT20050934

Description

Myelodysplastic Syndrome: Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Myelodysplastic Syndrome Therapeutics.
  • GlobalData epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Myelodysplastic Syndrome (MDS) infection in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029.
  • MDS is managed through a combination of supportive care, chemotherapy, and targeted therapies.
  • The MDS pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase III development, and 87 assets in Phase II.
  • Over the past decade, 1,229 clinical trials have been conducted in MDS.
  • During the past decade, partnerships were most prevalent in North America and Europe.
Scope

GlobalData’s Myelodysplastic Syndrome Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the Myelodysplastic Syndrome Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Myelodysplastic Syndrome Therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

84 Pages
  • Key Findings
    • Disease Etiology
    • Epidemiology Overview - Diagnosed Prevalent Cases of MDS in 2024 and 2028
  • Treatment Overview
    • Marketed Drugs - Leading Marketed Drugs in MDS
    • Marketed Drugs - Overview by Mechanism of Action
    • Marketed Drugs - Overview by Molecule type
    • Marketed Drug Profile - Novartis’s Gleevec/Glivec
    • Marketed Drug Profile - BMS’s Vidaza
    • Marketed Drug Profile - BMS’s Revlimid
    • Marketed Drug Profile - Geron’s Rytelo
    • Marketed Drug Profile - Otsuka Pharmaceutical’s Inaqovi/Inqovi
    • Marketed Drug Profile - BMS’s Reblozyl
    • Marketed Drug Profile - Servier Pharmaceutical’s Tibsovo
    • Marketed Drug Profile - Shorla Oncology’s Imkeldi
    • Marketed Drug Profile - Eisai ’s Dacogen/Dake
    • Marketed Drugs - Annual Cost of Therapy
    • Marketed Drugs - Time to Pricing and Reimbursement for Vidaza
    • Marketed Drugs - Time to Pricing and Reimbursement for Revlimid
    • Marketed Drugs - Time to Pricing and Reimbursement for Inqovi
    • Marketed Drugs - Time to Pricing and Reimbursement for Gleevec/Glivec
    • Marketed Drugs - Time to Pricing for Rytelo and Tibsovo
    • Pipeline Drugs Overview - Late-Stage Pipeline Drugs in MDS
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - PTSR and LoA in MDS & Oncology
    • Pipeline Drugs - PTSR and LoA in MDS
    • Clinical Trials in MDS - Historical Overview
    • Clinical Trials in MDS - Overview by Phase
    • Clinical Trials in MDS - Overview by Status
    • Clinical Trials in MDS - Overview by Phase for Ongoing and Planned Trials
    • Clinical Trials in MDS - Trials with a Virtual Component
    • Clinical Trials in MDS - Geographic Overview
    • Clinical Trials in MDS - Single-Country and Multinational Trials by Region
    • Clinical Trials in MDS - Top Sponsors with Breakdown by Phase
    • Clinical Trials in MDS - Top Sponsors with Breakdown by Status
    • Clinical Trials in MDS - Overview by Endpoint Status
    • Clinical Trials in MDS - Overview by Race and Ethnicity
    • Trials in MDS - Enrollment Data
    • Clinical Trials in MDS - Overview of Sites by Geography
    • Clinical Trials in MDS - Top 20 Countries for Trial Sites
    • Clinical Trials in MDS - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for MDS
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in MDS by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in MDS
    • Commercial Assessment - Key Market Players in MDS
    • Future Market Catalysts - Upcoming Market Catalysts in MDS
    • Methodology - Sales Forecasts
    • Methodology - Pricing and Reimbursement
    • Methodology - PTSR and LoA Analysis

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us